Saman Maleki
Dr. Maleki received his M.Sc. in Microbiology from the University of Isfahan in Iran. He then obtained his Ph.D. in Microbiology and Immunology from Western University in Canada where he held a full scholarship for his entire post-graduate studies. During his Ph.D., he studied the dual role of mTOR inhibition on anti-tumor and allogeneic immune responses. He also discovered a novel role for indoleamine-2,3-dioxygenase (IDO) on resistance to chemotherapy and radiation therapy. During his Ph.D., Dr. Maleki has received multiple research and travel awards and has published multiple peer-reviewed publications. Dr. Maleki continued his research on cancer immunotherapy and targeting DNA repair pathways in tumors at the Lawson Health Research Institute where he has been involved in several Immuno-Oncology drug development projects. Two phase I clinical trials on novel drugs that Dr. Maleki worked on are currently underway. Dr. Maleki’s current research interest involves studying the role of host versus tumor IDO on resistance to cancer immunotherapy and neoantigen formation in tumor cells. Throughout his research career, Dr. Maleki has been involved in educating public about the progress and promise of cancer research through many speaking engagements and writing articles for various media outlets. Because of his profound interest in knowledge translation, Dr. Maleki founded a biotech company to help take his research findings one step closer to clinical practice. Dr. Maleki is a CaRTT Emeritus member and shares his experience in cancer research and post-graduate studies with new CaRTT scholars.
